Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Covalon TechnologiesCVALF 85 Cash-to-Debt is 9.34 as of Mar. 2026, which is 27% above its 10-year median of 7.37. GuruFocus rates CVALF with a GF Score™ of 85/100 and a GF Value™ of $1.54 (Fairly Valued). The stock has 3 warning signs investors should review. Among 849 Medical Devices & Instruments companies, Covalon Technologies ranks better than 73.85% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Covalon Technologies's cash to debt ratio for the quarter that ended in Mar. 2026 was 9.34.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Covalon Technologiescould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Covalon Technologies's Cash-to-Debt or its related term are showing as below:
CVALF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06 Med: 7.37 Max: No Debt
Current: 9.34
During the past 13 years, Covalon Technologies's highest Cash to Debt Ratio was No Debt. The lowest was 0.06. And the median was 7.37.
CVALF's Cash-to-Debt is ranked better than 73.85% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: 1.69
vs CVALF: 9.34
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Covalon Technologies Cash-to-Debt Related Terms
Covalon Technologies Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Covalon Technologies's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Instruments & Supplies subindustry, Covalon Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Covalon Technologies Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Covalon Technologies's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Covalon Technologies's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Covalon Technologies (CVALF) has a Cash-to-Debt of 9.34 as of Mar. 2026. This is 27% above median its historical median of 7.37. Over the past decade, Covalon Technologies' Cash-to-Debt has ranged from 0.06 to 10,000.00. According to the industry distribution chart, Covalon Technologies ranks #222 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 26.1%.
Is Covalon Technologies' Cash-to-Debt too high?
Covalon Technologies' current Cash-to-Debt of 9.34 is 27% above median its 10-year median of 7.37. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.69. Covalon Technologies' value of 9.34 is 452.7% above this industry median. Based on the distribution chart, Covalon Technologies ranks #222 out of 849 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Covalon Technologies has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Covalon Technologies' Cash-to-Debt compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Covalon Technologies ranks #222 out of 849 companies for Cash-to-Debt. This puts Covalon Technologies in the upper half of its industry. The industry median Cash-to-Debt is 1.69. Covalon Technologies' value of 9.34 is 452.7% above this benchmark. Historically, Covalon Technologies' own Cash-to-Debt has ranged from 0.06 to 10,000.00 over the past decade. While the company's 10-year median is 7.37 vs. the industry median of 1.69, Covalon Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.69, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Covalon Technologies's current Cash-to-Debt of 9.34 is 452.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Covalon Technologies's current Cash-to-Debt is 9.34, which is 27% above median its own 10-year median of 7.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Covalon Technologies stock overvalued right now?
Based on GuruFocus' analysis, Covalon Technologies (CVALF) is currently considered Fairly Valued. The stock's GF Value™ is $1.54, compared to a current price of $1.67 — trading 8.1% above its estimated fair value. The current Cash-to-Debt is 9.34, which is 27% above median its 10-year median of 7.37 and 452.7% above the Medical Devices & Instruments industry median of 1.69. Covalon Technologies' overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Covalon Technologies (CVALF), the current Cash-to-Debt is 9.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Covalon Technologies (CVALF) Overvalued in 2026?
Based on GuruFocus' analysis, Covalon Technologies stock appears to be overvalued.
The current stock price of $1.67 is trading 8.1% above its estimated GF Value™ of $1.54.
GuruFocus considers Covalon Technologies to be Fairly Valued.
Key valuation signals for CVALF:
Cash-to-Debt: 9.34 (27% above median its 10-year median of 7.37)
GF Value™: $1.54 vs. price of $1.67 (8.1% above fair value)
Industry Position: 452.7% above the Medical Devices & Instruments median (#222 of 849)
No single metric tells the full story. See the CVALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Covalon Technologies Ltd is engaged in the business of researching, developing, manufacturing, and marketing patent-protected medical products that improve patient outcomes in the areas of infection management, wound care, and surgical procedures. The company generates revenue through development contracts, licensing agreements, distribution contracts, and sales. Its products include IV dressings, surgical site protection products, vascular access protection products, and others, and its solutions include primary dressing cover, vascular access technologies, advanced wound care, sensitive skin solutions, custom medical coatings, and patient resource support.
85GF Score
Get the complete analysis for CVALF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVALF has been successfully added to your 
